Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
A Study to Assess Safety and Efficacy of CHO-H01 as a Single Agent/Combined With Lenalidomide in Subjects With Refractory or Relapsed Non-Hodgkin's LymphomaHemic and Lymphatic Diseases, Neoplasms by Histologic Type, follicular lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm, non-Hodgkin lymphomaActive, not recruitingPhase 1 / Phase 22026-08-17NCT05950165

1 results · Page 1 of 1

Swipe the table sideways for more columns.

OrganizationsLinked trials
Cho Pharma Inc.3

9 results · Page 1 of 1

Swipe the table sideways for more columns.